Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPTLC2 | O15270 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19893251 | 1.00 | SPTLC2 (0.59) | SPTLC2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL20262250 | 0.86 | SPTLC2 (0.52) | SPTLC2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL19892997 | 0.81 | SPTLC2 (0.49) | SPTLC2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL19892996 | 0.81 | SPTLC2 (0.49) | SPTLC2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL9028457 | 0.80 | LMNA (0.62) | LMNAL3MBTL1ALDH1A1POLBCYP2C19 | |
| SCHEMBL19893421 | 0.78 | LMNA (0.51) | SPTLC2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL19893419 | 0.78 | LMNA (0.51) | SPTLC2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL20262249 | 0.76 | LMNA (0.49) | SPTLC2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL19892770 | 0.74 | SPTLC2 (1.00) | SPTLC2LMNAL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL19893235 | 0.74 | SPTLC2 (1.00) | SPTLC2LMNAL3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3287441-B1 | ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10189785-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-3287441-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189785-B2 | Heterocyclic compound | SPTLC1, SPTLC2, NPC1 | SPTLC2 2/4885LMNA 1309/4885L3MBTL1 1604/4885 |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | SPTLC1, SPTLC2, NPC1 | SPTLC2 2/4885LMNA 1309/4885L3MBTL1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.